João Vieira | Head of Discovery
Argenx Bv
I have worked for several years in the identification and engineering of single-domain antibodies (sdAb) derived from camelids, for multiple therapeutic and research programs at Ablynx and in a crop protection setting at Agrosavfe (Biotalys). After that I switched receptor platforms and I joined a cell therapy company, Adaptimmune, leading teams in optimizing T cell receptors (TCR) to treat solid tumors and also leading matrixed projects, including the new HIT (HLA-Independent TCR) approach in collaboration with Astellas.
Currently I am head of Discovery at argenx, I oversee the discovery and lead Antibody identification for multiple autoimmune projects, as well as scouting for the next new projects/collaborations through our Immunology Innovation Program.
Appearances:
Festival of Biologics Day 2 @ 17:40
Development of ARGX-117, an antibody targeting complement factor C2
ARGX-117 is a human IgG1 monoclonal antibody designed to reduce tissue inflammation resulting from activation of the classical and lectin complement pathways. It binds and inhibits C2 in a pH- and calcium-dependent fashion. In the Fc, mutations to reduce effector functions and for half life extension were introduced. A phase 1 study in healthy human subjects is currently ongoing to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single and multiple ascending dose levels of ARGX-117. An interim analysis of this study has been conducted and will be presented.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events